148 related articles for article (PubMed ID: 1895208)
21. The 90K tumor-associated antigen and clinical progression in human immunodeficiency virus infection.
Iacobelli S; Ullrich A; Tinari N; Ortona L; Tamburrini E; D'Egidio M; Ghinelli F; Sighinolfi L; Piazza M; Chirianni A
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(4):450-6. PubMed ID: 7583441
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of combined response markers among human immunodeficiency virus-infected persons: possible aid in the decision to change zidovudine monotherapy.
Graham NM; Park LP; Piantadosi S; Phair JP; Mellors J; Fahey JL; Saah AJ
Clin Infect Dis; 1995 Feb; 20(2):352-62. PubMed ID: 7742442
[TBL] [Abstract][Full Text] [Related]
23. Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections.
Miles SA; Wang HJ; Cortes E; Carden J; Marcus S; Mitsuyasu RT
Ann Intern Med; 1990 Apr; 112(8):582-9. PubMed ID: 2109563
[TBL] [Abstract][Full Text] [Related]
24. The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals.
Bass HZ; Hardy WD; Mitsuyasu RT; Taylor JM; Wang YX; Fischl MA; Spector SA; Richman DD; Fahey JL
J Acquir Immune Defic Syndr (1988); 1992; 5(3):215-21. PubMed ID: 1346807
[TBL] [Abstract][Full Text] [Related]
25. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group.
Dezube BJ; Pardee AB; Chapman B; Beckett LA; Korvick JA; Novick WJ; Chiurco J; Kasdan P; Ahlers CM; Ecto LT
J Acquir Immune Defic Syndr (1988); 1993 Jul; 6(7):787-94. PubMed ID: 8099612
[TBL] [Abstract][Full Text] [Related]
26. [ Biological criteria for prediction of the clinical course leading to AIDS].
Salmon D; Couroucé AM; Doinel C; Fine JM; Kaplan C; Lambin P; Lefrère JJ; Rouger P; Salmon C
Rev Fr Transfus Hemobiol; 1990 Dec; 33(6):407-14. PubMed ID: 1981002
[No Abstract] [Full Text] [Related]
27. Dependence of the hazard of AIDS on markers.
Yong FH; Taylor JM; Bryant JL; Chmiel JS; Gange SJ; Hoover D
AIDS; 1997 Feb; 11(2):217-28. PubMed ID: 9030370
[TBL] [Abstract][Full Text] [Related]
28. Close relationships between neopterin and beta-2-microglobulin levels in intravenous drug abusers.
Lin RY; Nygren E; Valinsky J; Lorenzana FG; Ralph H
Int Arch Allergy Appl Immunol; 1990; 91(4):389-93. PubMed ID: 1976599
[TBL] [Abstract][Full Text] [Related]
29. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS).
Krown SE; Gold JW; Niedzwiecki D; Bundow D; Flomenberg N; Gansbacher B; Brew BJ
Ann Intern Med; 1990 Jun; 112(11):812-21. PubMed ID: 1971504
[TBL] [Abstract][Full Text] [Related]
30. Enhanced serum levels of beta-2-microglobulin, neopterin, and interferon-gamma in patients treated with recombinant tumor necrosis factor-alpha.
Aulitzky WE; Tilg H; Herold M; Berger M; Vogel W; Judmaier G; Gastl G; Mull B; Flener R; Wiegele J
J Interferon Res; 1988 Oct; 8(5):655-64. PubMed ID: 3148671
[TBL] [Abstract][Full Text] [Related]
31. [Serum neopterin and beta2-microglobulin concentration as "prognostic markers" of AIDS].
Halota W; Jaruga B; Pawłowska M
Pol Merkur Lekarski; 2002 Aug; 13(74):126-8. PubMed ID: 12420343
[TBL] [Abstract][Full Text] [Related]
32. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion.
Mellors JW; Kingsley LA; Rinaldo CR; Todd JA; Hoo BS; Kokka RP; Gupta P
Ann Intern Med; 1995 Apr; 122(8):573-9. PubMed ID: 7887550
[TBL] [Abstract][Full Text] [Related]
33. Effect of azidothymidine (AZT) on HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD8, soluble interleukin-2 receptor and tumor necrosis factor alpha levels in patients with AIDS-related complex or AIDS.
Reddy MM; McKinley G; Englard A; Grieco MH
Int J Immunopharmacol; 1990; 12(7):737-41. PubMed ID: 2127261
[TBL] [Abstract][Full Text] [Related]
34. Cytokine network and acute primary HIV-1 infection.
Sinicco A; Biglino A; Sciandra M; Forno B; Pollono AM; Raiteri R; Gioannini P
AIDS; 1993 Sep; 7(9):1167-72. PubMed ID: 8216972
[TBL] [Abstract][Full Text] [Related]
35. Surrogate markers for AIDS treatment.
Jacobson M
Nurs Times; 1991 May 29-Jun 4; 87(22):49. PubMed ID: 1675013
[No Abstract] [Full Text] [Related]
36. Changes in serum neopterin and serum beta 2-microglobulin in subjects with lung infections.
Carstens J; Andersen PL
Eur Respir J; 1994 Jul; 7(7):1233-8. PubMed ID: 7925900
[TBL] [Abstract][Full Text] [Related]
37. Tracking of markers and onset of disease among HIV-1 seroconverters.
Galai N; Muñoz A; Chen K; Carey VJ; Chmiel J; Zhou SY
Stat Med; 1993 Nov; 12(22):2133-45. PubMed ID: 7906051
[TBL] [Abstract][Full Text] [Related]
38. Temporary increase in serum beta 2-microglobulin during treatment with interferon-alpha for AIDS-associated Kaposi's sarcoma.
de Wit R; Bakker PJ; Reiss P; Hoek FJ; Lange JM; Goudsmit J; Veenhof KH
AIDS; 1990 May; 4(5):459-62. PubMed ID: 2196909
[TBL] [Abstract][Full Text] [Related]
39. Serum neopterin changes in HIV-infected subjects: indicator of significant pathology, CD4 T cell changes, and the development of AIDS.
Melmed RN; Taylor JM; Detels R; Bozorgmehri M; Fahey JL
J Acquir Immune Defic Syndr (1988); 1989; 2(1):70-6. PubMed ID: 2783972
[TBL] [Abstract][Full Text] [Related]
40. [HIV-1 antigenemia and T-cell activation in HIV-1 infected patients].
Harrer T; Wolf B; Kersten W; Schwarz W; Bergner D; Kalden JR
Klin Wochenschr; 1990 Sep; 68(17):864-8. PubMed ID: 2214610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
